Clinical Trials Logo

Retinal Disease clinical trials

View clinical trials related to Retinal Disease.

Filter by:

NCT ID: NCT04125043 Completed - Retinal Disease Clinical Trials

Accuracy of the Red Reflex Test in the Pediatric Population

Start date: March 1, 2020
Phase:
Study type: Observational

This study is designed to investigate the sensitivity and specificity of the Red Reflex Test (RRT), with and without dilation, for early detection of ocular abnormalities in children and newborns. The RRT functions by shining a light from an ophthalmoscope into a participant's eye and noting the presence or absence of a red glow. Despite its use in pediatric clinics for years, this test at times fails to detect significant ocular diseases, especially located in the back of the eye, threatening visual development in this population. Therefore, the investigators aim to quantify the utility of this test as a tool for screening by comparing these findings on RRT with those of retinal photography. The investigators hypothesize that the sensitivity and specificity of the RRT will be sufficient for detecting anterior segment pathology but will be insufficient for detecting posterior segment pathology with or without dilation.

NCT ID: NCT04123626 Active, not recruiting - Eye Diseases Clinical Trials

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

AURORA
Start date: October 7, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses. Single injections will be assessed in an open label way, and repeat injections will be assessed in a double-masked, randomized, sham-controlled fashion.

NCT ID: NCT04110015 Terminated - Glaucoma Clinical Trials

Assessment of Visual Function in Ophthalmic Disorders Using Virtual Visual Field Analysis

proVVF
Start date: October 1, 2020
Phase:
Study type: Observational

1. To evaluate the accuracy of virtual visual field (VVF) headsets equipped the standard visual field software in its ability to assess visual function in various retinal, glaucoma and neuro-ophthalmic disorders by comparing retinal fundus and optic nerve images, optical coherence tomography and neuroimages to the VVF produced. 2. To test the null hypothesis that VVF testing compares favorably to the gold standard, Humphrey visual field (HVF) by comparing testing time, mean sensitivity, markers of reliability including false positives and negatives and fixation losses and global indices such as mean deviation and pattern standard deviation.

NCT ID: NCT04003831 Completed - Retinal Disease Clinical Trials

Navigated OCT Imaging With the P200TxE

Start date: June 13, 2019
Phase: N/A
Study type: Interventional

The P200TxE will be used to obtain peripheral OCT (optical coherence tomography) images.

NCT ID: NCT03954626 Completed - Clinical trials for Age-Related Macular Degeneration

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

Start date: June 7, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to collect ECG data after a single IVT injection of brolucizumab 6 mg in patients with neovascular age-related macular degeneration (nAMD).

NCT ID: NCT03913143 Active, not recruiting - Eye Diseases Clinical Trials

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

ILLUMINATE
Start date: April 4, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this double-masked, randomized, controlled, multiple-dose study is to evaluate the efficacy, safety, tolerability and systemic exposure of sepofarsen (QR-110) administered via intravitreal injection in subjects with Leber's Congenital Amaurosis (LCA) due to the CEP290 p.Cys998X mutation after 24 months of treatment

NCT ID: NCT03913130 Terminated - Eye Diseases Clinical Trials

Extension Study to Study PQ-110-001 (NCT03140969)

INSIGHT
Start date: May 13, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.

NCT ID: NCT03902925 Completed - Clinical trials for Diabetic Retinopathy

Pain During Pars Plana Vitrectomy With Sub-tenon Anesthesia

Start date: January 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Vitreoretinal surgery has evolved to less invasive procedures, and it is used to treat a wide range of diseases. So anesthesia for vitreoretinal procedures has evolved, promoting adequate analgesia while reducing risks to the patient. In the present study two types of procedures for anesthesia during vitreoretinal surgery are evaluated regarding the pain referred by the patient during the whole procedure: peribulbar anesthesia versus sub-tenon injection plus topical jelly anesthesia. Through the comparative analysis of the pain scale of the two groups it is expected that the two modalities present the same anesthetic efficacy, showing that the methods used may be equivalent.

NCT ID: NCT03894020 Active, not recruiting - Clinical trials for Macular Degeneration

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

Start date: January 8, 2019
Phase:
Study type: Observational

An observational study to evaluate the natural progression of dry AMD in genetically defined subjects

NCT ID: NCT03872479 Active, not recruiting - Retinal Disease Clinical Trials

Single Ascending Dose Study in Participants With LCA10

Start date: September 26, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal injection in participants with LCA10 caused by a homozygous or compound heterozygous mutation involving c.2991+1655A>G in intron 26 of the CEP290 gene ("LCA10-IVS26").